摘要
背景:肠道微生物不仅在营养物质的消化吸收中起着重要的作用,而且在维持宿主免疫、代谢和肠道屏障等方面起着重要的作用。最近cE表明肠道微生物区系的改变在代谢紊乱的发病机制中起着重要作用。 目的与方法:本文就肠道微生物群与肥胖、2型糖尿病、非酒精性脂肪肝等代谢紊乱的关系作一综述。d有关调整干预措施的贡献,侧重于最近的人类研究。 结果:几项研究已经确定了肠道微生物群与代谢紊乱之间的潜在因果关系,以及潜在的机制。调节干预的效果CHAS益生菌、益生菌、粪便微生物移植和其他新的治疗这些代谢紊乱的可能性也已被报道。 结论:越来越多的证据凸显在肠道菌群失调的发展的作用,从而影响宿主代谢与疾病表型。进一步的研究需要为了阐明肠道微生物衍生介质诱发代谢紊乱的确切机制,并通过调节干预在人类身上发挥其有益作用。肠道微生物区系提出了一种新的潜在治疗靶点的一系列代谢紊乱。
关键词: 肠道微生物,肥胖,2型糖尿病,非酒精性脂肪肝,益生菌,益生菌,粪便微生物移植。
Current Medicinal Chemistry
Title:Gut Microbiota as a Therapeutic Target for Metabolic Disorders
Volume: 25 Issue: 9
关键词: 肠道微生物,肥胖,2型糖尿病,非酒精性脂肪肝,益生菌,益生菌,粪便微生物移植。
摘要: Background: Gut microbiota play a vital role not only in the digestion and absorption of nutrients, but also in homeostatic maintenance of host immunity, metabolism and the gut barrier. Recent evidence suggests that gut microbiota alterations contribute to the pathogenesis of metabolic disorders.
Objective and Method: In this review, we discuss the association between the gut microbiota and metabolic disorders, such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease, and the contribution of relevant modulating interventions, focusing on recent human studies.
Results: Several studies have identified potential causal associations between gut microbiota and metabolic disorders, as well as the underlying mechanisms. The effects of modulating interventions, such as prebiotics, probiotics, fecal microbiota transplantation, and other new treatment possibilities on these metabolic disorders have also been reported.
Conclusion: A growing body of evidence highlights the role of gut microbiota in the development of dysbiosis, which in turn influences host metabolism and disease phenotypes. Further studies are required to elucidate the precise mechanisms by which gut microbiota-derived mediators induce metabolic disorders and modulating interventions exert their beneficial effects in humans. The gut microbiota represents a novel potential therapeutic target for a range of metabolic disorders.
Export Options
About this article
Cite this article as:
Gut Microbiota as a Therapeutic Target for Metabolic Disorders, Current Medicinal Chemistry 2018; 25 (9) . https://dx.doi.org/10.2174/0929867324666171009121702
DOI https://dx.doi.org/10.2174/0929867324666171009121702 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Cardiovascular Morbidity and Mortality in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Cystatin C, Adipokines and Cardiovascular Risk in HIV Infected Patients
Current HIV Research Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Bone Disease in Diabetes
Current Diabetes Reviews Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ
Current Vascular Pharmacology Transdermal Innovations in Diabetes Management
Current Diabetes Reviews Update on the Important New Drug Target in Cardiovascular Medicine – the Vascular Glycocalyx
Cardiovascular & Hematological Disorders-Drug Targets